Susan O’Brien

8.2k total citations · 3 hit papers
73 papers, 5.9k citations indexed

About

Susan O’Brien is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Susan O’Brien has authored 73 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Genetics, 47 papers in Hematology and 23 papers in Rheumatology. Recurrent topics in Susan O’Brien's work include Chronic Lymphocytic Leukemia Research (55 papers), Chronic Myeloid Leukemia Treatments (38 papers) and Eosinophilic Disorders and Syndromes (23 papers). Susan O’Brien is often cited by papers focused on Chronic Lymphocytic Leukemia Research (55 papers), Chronic Myeloid Leukemia Treatments (38 papers) and Eosinophilic Disorders and Syndromes (23 papers). Susan O’Brien collaborates with scholars based in United States, United Kingdom and Germany. Susan O’Brien's co-authors include Jörge E. Cortes, Hagop M. Kantarjian, Francis J. Giles, Moshe Talpaz, Guillermo Garcia‐Manero, Stefan Faderl, Jianqin Shan, Claude Nicaise, Michael J. Keating and Neil P. Shah and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Susan O’Brien

72 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

2006 1.3k citations Moshe Talpaz, Neil P. Shah et al. New England Journal of Medicine profile →
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

2006 970 citations Hagop M. Kantarjian, Francis J. Giles et al. New England Journal of Medicine profile →
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia

2000 586 citations Hagop M. Kantarjian, Susan O’Brien et al. profile →

Peers

Countries citing papers authored by Susan O’Brien

Since Specialization

Citations

This map shows the geographic impact of Susan O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan O’Brien more than expected).

Fields of papers citing papers by Susan O’Brien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan O’Brien. The network helps show where Susan O’Brien may publish in the future.

Co-authorship network of co-authors of Susan O’Brien

This figure shows the co-authorship network connecting the top 25 collaborators of Susan O’Brien. A scholar is included among the top collaborators of Susan O’Brien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan O’Brien. Susan O’Brien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial 2023 ·Blood ·John F. Seymour, John C. Byrd, Paolo Ghia, Arnon P. Kater, Asher Chanan‐Khan, Richard R. Furman, Susan O’Brien, Jennifer R. Brown, Talha Munir, Anthony R. Mato, Stephan Stilgenbauer, (unknown), (unknown), Kara Higgins, (unknown), (unknown), Wojciech Jurczak, Jennifer A. Woyach	62
2	Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis 2014 ·Leukemia & lymphoma ·Michelle Poon, Patricia S. Fox, Barry I. Samuels, Susan O’Brien, Elias Jabbour, Yvonne Hsu, Alison Gulbis, Martin Körbling, Richard Champlin, Lynne V. Abruzzo, Roland L. Bassett, Issa F. Khouri	9
3	The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment 2013 ·Expert Review of Hematology ·Nitin Jain, Susan O’Brien	9
4	Chronic Myelogenous Leukemia 2012 ·Journal of the National Comprehensive Cancer Network ·Susan O’Brien, Camille N. Abboud, Mojtaba Akhtari, Jessica K. Altman, Ellin Berman, Daniel J. DeAngelo, Steven M. Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Javier Pinilla‐Ibarz, Jerald P. Radich, Vishnu Reddy, Neil P. Shah, Paul J. Shami, Benjamin D. Smith, David S. Snyder, Meir Wetzler, Furhan Yunus	20
5	Small Lymphocytic Lymphoma and Chronic Lymphocytic Leukemia 2012 ·The Cancer Journal ·Fabio P S Santos, Susan O’Brien	46
6	Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib 2011 ·Cancer ·Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Jianqin Shan, Elias Jabbour, Lynne V. Abruzzo, Srđan Verstovšek, Guillermo Garcia‐Manero, Susan O’Brien, Jörge E. Cortes	14
7	Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia 2010 ·Leukemia Research ·Jean-Marie Bruey, Hagop M. Kantarjian, Wanlong Ma, Zeev Estrov, Chen-Hsiung Yeh, Amber C. Donahue, Heather Sanders, Susan O’Brien, Michael J. Keating, Maher Albitar	11
8	The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities 2009 ·Cancer ·Hagop M. Kantarjian, Susan O’Brien, Farhad Ravandi, Gautam Borthakur, Stefan Faderl, Carlos E. Bueso‐Ramos, Lynne V. Abruzzo, Sherry Pierce, Jianqin Shan, Jean‐Pierre J. Issa, Guillermo Garcia‐Manero	34
9	Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long‐term outcome of patients with early chronic myeloid leukemia in chronic phase 2009 ·Cancer ·Yesid Alvarado, Hagop M. Kantarjian, Susan O’Brien, Stefan Faderl, Gautam Borthakur, Jan A. Burger, William G. Wierda, Guillermo Garcia‐Manero, Jianqin Shan, Jörge E. Cortes	74
10	An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation 2008 ·Leukemia Research ·Iman Jilani, Hagop M. Kantarjian, (unknown), M. Gorre, Jörge E. Cortes, Oliver G. Ottmann, Kapil N. Bhalla, Susan O’Brien, Francis J. Giles, Maher Albitar	12
11	Kinase domain point mutations in Philadelphia chromosome‐positive acute lymphoblastic leukemia emerge after therapy with BCR‐ABL kinase inhibitors 2008 ·Cancer ·Dan Jones, Deborah Thomas, C. Cameron Yin, Susan O’Brien, Jörge E. Cortes, Elias Jabbour, (unknown), Francis J. Giles, Weiqiang Zhao, Hagop M. Kantarjian	96
12	New Targeted Therapies for Chronic Myelogenous Leukemia: Opportunities to Overcome Imatinib Resistance 2007 ·Seminars in Hematology ·Elias Jabbour, Jörge E. Cortes, Susan O’Brien, Francis J. Giles, Hagop M. Kantarjian	24
13	Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL breakdown → 2006 ·New England Journal of Medicine ·Hagop M. Kantarjian, Francis J. Giles, Lydia Wunderle, Kapil N. Bhalla, Susan O’Brien, Barbara Waßmann, Chiaki Tanaka, Paul W. Manley, P. Rae, William Mietlowski, (unknown), Andreas Hochhaus, James D. Griffin, Dieter Hoelzer, Maher Albitar, Margaret Dugan, Jörge E. Cortes, Leila Alland, Oliver G. Ottmann	970
14	T-cell large granular lymphocytic (T-LGL) leukemia: Experience in a single institution over 8 years 2006 ·Leukemia Research ·Ahmed Aribi, Yang O. Huh, Michael A. Keating, Susan O’Brien, Alessandra Ferrajoli, Stefan Faderl, William G. Wierda, Hagop Kantarjian, Farhad Ravandi	27
15	Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias breakdown → 2006 ·New England Journal of Medicine ·Moshe Talpaz, Neil P. Shah, Hagop M. Kantarjian, Nicholas J. Donato, John Nicoll, Ron Paquette, Jörge E. Cortes, Susan O’Brien, Claude Nicaise, Eric Bleickardt, (unknown), Vishwanath R. Iyer, Tai‐Tsang Chen, Fei Huang, Arthur P. DeCillis, Charles L. Sawyers	1288
16	Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia 2004 ·Cancer ·Carlos E. Bueso‐Ramos, Jörge E. Cortes, Moshe Talpaz, Susan O’Brien, Francis J. Giles, Mary Beth Rios, L. Jeffrey Medeiros, Hagop Kantarjian	44
17	Results of Therapy with Interferon Alpha and Cyclic Combination Chemotherapy in Patients with Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Early Chronic Phase 2001 ·Leukemia & lymphoma ·(unknown), Hagop M. Kantarjian, Susan O’Brien, (unknown), Jörge E. Cortes, Miloslav Beran, Charles Koller, Michael R. Keating, Moshe Talpaz	10
18	Survival of Young Patients with Chronic Lymphocytic Leukemia Failing Fludarabine Therapy: A Basis for the Use of Myeloablative Therapies 1995 ·Leukemia & lymphoma ·John F. Seymour, L. E. Robertson, Susan O’Brien, Susan Lerner, Michael J. Keating	20
19	The Expanding Role of Fludarabine in Hematologic Malignancies 1994 ·Leukemia & lymphoma ·Michael J. Keating, Susan O’Brien, (unknown), Hagop M. Kantarjian, Meletios Α. Dimopoulos, Peter McLaughlin, Fernando Cabanillas, V. Grégoire, (unknown), Varsha Gandhi, Elihu H. Estey, William Plunkett	21
20	Differential dose‐related haematological effects of GM‐CSF in pancytopenia: evidence supporting the advantage of low‐ over high‐dose administration in selected patients 1991 ·British Journal of Haematology ·Razelle Kurzrock, Moshe Talpaz, (unknown), Elihu H. Estey, Susan O’Brien, Cheryl Hirsch‐Ginsberg, Charles Koller, Emil J. Freireich, Jordan U. Gutterman	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact